Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제35권2호
  • /
  • Pages.106-111
  • /
  • 2009
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지

Oral bisphosphonates induced osteonecrosis of the mandible : A case report

  • Son, Hyo-Jeong (Department of oral and maxillofacial surgery, LivingWell Dental Hospital) ;
  • Jang, Ho-Yeol (Department of oral and maxillofacial surgery, LivingWell Dental Hospital) ;
  • Keum, Yun-Seon (Department of oral and maxillofacial surgery, LivingWell Dental Hospital) ;
  • Lee, Jang-Yeol (Department of oral and maxillofacial radiology, LivingWell Dental Hospital) ;
  • Kim, Hyoun-Chull (Department of oral and maxillofacial surgery, LivingWell Dental Hospital) ;
  • Lee, Sang-Chull (Department of oral and maxillofacial surgery, LivingWell Dental Hospital)
  • 발행 : 2009.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bisphosphonates have been approved for Paget's disease, cancer-related hypercalcemia, bone involvement in multiple myeloma or solid tumors and osteoporosis. Although, underlying pathophysiological mechanisms remain unclear, it seems that bisphosphonates inhibit osteoclast precursor cells, modulate migratory and adhesive characteristics and induce apoptosis of osteoclasts. Furthermore impacts on angiogenesis, microenvironment and signal transduction between osteoclasts and osteoblasts. In this report, we present a case of oral bisphosphonates induced osteonecrosis of the mandible in a 84-year-old patient who received for two years. Two tapered screw vent implants(Zimmer, USA) were placed in the area of first and second molar. Two weeks later after crowns restored, some inflammatory signs and symptoms were observed on the second molar area. Sequestrum was formed and the sequestrum was removed with the implant. Frequent follow-up checks and oral hygiene maintenances were done and the first molar implant was restored. There is insufficient evidence suggests that duration of oral bisphosphonate therapy correlates with the development and severity of osteonecrosis. Therefore, dentists should not overlook the possibility of development of bisphosphonate induced osteonecrosis in patients who have taken oral forms of medication for less than three years.

키워드

참고문헌

  1. Mathes SJ: Plastic surgery. Saunders Elsevier Company; 2006;209-234
  2. Melo MD, Obeid G: Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition J Am Dent Assoc 2005;136(12): 1675-8 https://doi.org/10.14219/jada.archive.2005.0110
  3. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 2003;61:1115-7 https://doi.org/10.1016/S0278-2391(03)00720-1
  4. Hoff A: Expert panel recommendation for prevention, diagnosis,and treatment of osteonecrosis of the jaws Oncology Drug Advisory Committee Meeting East Hanover, NJ, Novartis, March 4, 2005
  5. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 2005;23:8580-7 https://doi.org/10.1200/JCO.2005.02.8670
  6. Marx RE: Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment Hanover Park(IL) Quintessence Publsihing 2006
  7. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 2007; 65:369-76
  8. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB: Managing the care of patients with bis phosphonate associated osteonecrosis: an American Academy of Oral Medicine position paper J Am Dent Assoc 2005;136(12):1658-68 https://doi.org/10.14219/jada.archive.2005.0108
  9. Catalano L, Del Vecchio S, Petruzzie llo F, et al: Sestamibi and FDGPET scans to support diagnosis of jaw osteonecrosis Ann Hematol 2007;86(6):415-23 https://doi.org/10.1007/s00277-007-0263-0
  10. Russell RG: Bisphosphonates: mode of action and pharmacology Pediatrics 2007;119 Suppl 2:S150-62 https://doi.org/10.1542/peds.2006-2023H
  11. Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status Clin Cancer Res 2006;12(20 Pt 2):6222-30 https://doi.org/10.1158/1078-0432.CCR-06-0843
  12. Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 2007;65(3):415-23 https://doi.org/10.1016/j.joms.2006.10.061
  13. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D,Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid Haematologica 2006;91(7):968-71
  14. Yoh Sawatari, Robert E: Marx, Bisphosphonates and Bisphosphonate Induced Osteonecrosis Oral Maxillofacial Surg Clin N Am 2007;19:487-98 https://doi.org/10.1016/j.coms.2007.07.003
  15. Marx RE, Sawatari Y, Fortin M, Broumand:. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 2005;63(11):1567-75 https://doi.org/10.1016/j.joms.2005.07.010
  16. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S: Possible association between diabetes and bisphosphonate- related jaw osteonecrosis J Clin Endocrinol Metab 2007;92(3):1172-5 https://doi.org/10.1210/jc.2006-2036
  17. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM et al: Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006; 17(8):1336-7 https://doi.org/10.1093/annonc/mdl045
  18. Hellstein JW, Marek CL: Bisphospho nate osteochemonecrosis (bis-phossy jaw):is this phossy jaw of the 21st century J Oral Maxillofac Surg 2005;63(5):682-9 https://doi.org/10.1016/j.joms.2005.01.010
  19. Van den Wyngaert T, Huizing MT, Vermorken JB: Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy Ann Oncol 2006; 17(8):1197-204 https://doi.org/10.1093/annonc/mdl294
  20. Courtney PA, Hosking DJ, Fairbairn K J, Deighton CM: Treatment of SAPHO with pamidronate. Rheumatology 2002; 41:1196-8 https://doi.org/10.1093/rheumatology/41.10.1196
  21. Marx RE: Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Quintessence Publishing Co Inc; 2007;9-96
  22. Advisory Task Force on Bisphospho nate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillo facial Surgeons position paper on bis phosphonate-related osteo necrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-76 https://doi.org/10.1016/j.joms.2006.11.003
  23. Jeffcoat MK: Safety of oral bisphosphonates: Controlled studies on alveolar bone Int J Oral Maxillofac Implants 2006;21:349
  24. Bao-Thy Grant, Chistopher Amenedo: Outcomes of placing dental implants in patients taking oral bisphosphonates: A review of 115 cases J Oral Maxillofac Surg 2008;66:223-230 https://doi.org/10.1016/j.joms.2007.09.019
  25. Starck WJ, Epker BN: Failure of osteointegrated dental implants after diphosphonate therapy for osteoporosis: A case report Int J Oral Mxillofac Implants 1995;10:74-8